Product Profiles: Targeted Cancer Therapies - Trend towards personalized medicine will lead to market fragmentation

Introduction

The targeted therapies class boasts several of the top-selling anticancer brands, and has fueled most of the recent rapid growth of the oncology market as a whole. In the next decade, several blockbuster targeted therapies will undergo patent expiries and the market will become more fragmented as new targeted therapies are developed for niche populations.

Features and benefits

• Includes targeted cancer therapy drug profiles and development overviews detailing the companies involved and the clinical data that led to approvals
• Includes SWOT analysis of each brand in the targeted cancer therapies class
• Overview of each brand’s positioning in its marketed indications relative to its competitors and in terms of its ability to meet unmet needs
• Analysis of the clinical and commercial attractiveness of the targeted cancer therapies

Highlights

• As a growing number of companies strive to develop targeted cancer therapies, competition will inevitably become more intense as more agents in this class reach the market. In addition, increasing pharmacoeconomic pressures will dampen sales growth of drugs in this market as they tend to command a high price.
• In recent years an improved understanding of the heterogeneity of cancer tumors and their molecular pathogenesis has led to the development of targeted therapies designed to treat niche subsets of patients with specific genetic mutations.
• The co-development of companion diagnostics that can identify the patients that will most benefit from cancer treatment will become increasingly important for developers seeking approval of targeted therapies and the treatment of cancer will become more personalized

Your key questions answered

• Access detailed information about the drugs that make up the most lucrative class in the oncology market
• Understand the key factors that led to the success of some targeted cancer therapy brands and the issues which have hindered the uptake of others
• Understand how the targeted cancer therapies market will change in the future as developers target niche indications

Table Of Contents

OVERVIEW
Catalyst
Summary

EXECUTIVE SUMMARY
Strategic scoping and focus
Datamonitor key findings
Related reports

PRODUCT OVERVIEW
Targeted cancer therapy brands

MARKETED PRODUCT PROFILES
Adcetris (brentuximab vedotin; Seattle Genetics/Takeda)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Afinitor (everolimus; Novartis)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Arzerra (ofatumumab; Genmab/GlaxoSmithKline)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Avastin (bevacizumab; Genentech/Roche/Chugai)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Caprelsa (vandetanib; AstraZeneca)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Gleevec (imatinib; Novartis)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Herceptin (trastuzumab; Roche/Chugai)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Iressa (gefitinib; AstraZeneca)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Istodax (romidepsin; Celgene)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Nexavar (sorafenib; Bayer Schering/Onyx)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Revlimid (lenalidomide; Celgene)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Rituxan (rituximab; Biogen Idec/Roche/Chugai/Zenyaku Kogyo)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Sprycel (dasatinib; Bristol-Myers Squibb)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Sutent (sunitinib; Pfizer)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Tarceva (erlotinib; OSI Pharmaceuticals/Genentech/Roche)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Tasigna (nilotinib; Novartis)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Thalomid (thalidomide; Celgene)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Torisel (temsirolimus; Pfizer)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Tykerb (lapatinib; GlaxoSmithKline)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Vectibix (panitumumab; Amgen)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Velcade (bortezomib; Takeda/Johnson & Johnson)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Votrient (pazopanib; GlaxoSmithKline)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Xalkori (crizotinib; Pfizer)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Yervoy (ipilimumab; Bristol-Myers Squibb)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Zelboraf (vemurafenib; Roche/Plexxikon)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Zolinza (vorinostat; Merck & Co.)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness

BIBLIOGRAPHY
Journal papers
Websites
Datamonitor reports
Other

APPENDIX
Market definition for the targeted cancer therapies class
Targeted cancer therapies by ATC class
Targeted cancer therapies not included in this report
Datamonitor drug assessment scorecard
Contributing experts
Conferences attended
Report methodology

LIST OF TABLES

Table: Targeted cancer therapy brands, 2011
Table: Adcetris (brentuximab vedotin; Seattle Genetics/Takeda) – drug profile, 2011
Table: Overview of pivotal trial data for Adcetris in cancer, 2011
Table: Datamonitor's drug assessment summary of Adcetris (brentuximab vedotin; Seattle Genetics/Takeda) in cancer, 2011
Table: Afinitor (everolimus; Novartis) – drug profile, 2011
Table: Overview of pivotal trial data for Afinitor in cancer, 2011
Table: Datamonitor's drug assessment summary of Afinitor (everolimus; Novartis) in cancer, 2011
Table: Arzerra (ofatumumab; Genmab/GlaxoSmithKline) – drug profile, 2011
Table: Overview of pivotal trial data for Arzerra in cancer, 2011
Table: Datamonitor's drug assessment summary of Arzerra (ofatumumab; Genmab/GlaxoSmithKline), 2011
Table: Avastin (bevacizumab; Roche/Chugai) – drug profile, 2011
Table: Overview of pivotal trial data for Avastin in cancer, 2011
Table: Datamonitor's drug assessment summary of Avastin (bevacizumab; Genentech/Roche/Chugai), 2011
Table: Caprelsa (vandetanib; AstraZeneca) – drug profile, 2011
Table: Overview of pivotal trial data for Caprelsa in cancer, 2011
Table: Datamonitor's drug assessment summary of Caprelsa (vandetanib; AstraZeneca), 2011
Table: Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA) – drug profile, 2011
Table: Overview of pivotal trial data for Erbitux in cancer, 2011
Table: Datamonitor's drug assessment summary of Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA), 2011
Table: Gleevec (imatinib; Novartis) – drug profile, 2011
Table: Overview of pivotal trial data for Gleevec in cancer, 2011
Table: Datamonitor's drug assessment summary of Gleevec (imatinib; Novartis), 2011
Table: Herceptin (trastuzumab; Roche/Chugai) – drug profile, 2011
Table: Overview of pivotal trial data for Herceptin in cancer, 2011
Table: Datamonitor's drug assessment summary of Herceptin (trastuzumab; Roche/Chugai), 2011
Table: Iressa (gefitinib; AstraZeneca) – drug profile, 2011
Table: Overview of pivotal trial data for Iressa in cancer, 2011
Table: Datamonitor's drug assessment summary of Iressa (gefitinib; AstraZeneca), 2011
Table: Istodax (romidepsin; Celgene) – drug profile, 2011
Table: Overview of pivotal trial data for Istodax in cancer, 2011
Table: Nexavar (sorafenib; Bayer Schering/Onyx) – drug profile, 2011
Table: Overview of pivotal trial data for Nexavar in cancer, 2011
Table: Datamonitor's drug assessment summary of Nexavar (sorafenib; Bayer Schering/Onyx), 2011
Table: Revlimid (lenalidomide; Celgene) – drug profile, 2011
Table: Overview of pivotal trial data for Revlimid in cancer, 2009
Table: Datamonitor's drug assessment summary of Revlimid (lenalidomide; Celgene), 2011
Table: Rituxan (rituximab; Biogen Idec/Roche/Chugai/Zenyaku Kogyo) – drug profile, 2011
Table: Overview of pivotal trial data for Rituxan in cancer, 2011
Table: Datamonitor's drug assessment summary of Rituxan (rituximab; Biogen Idec/Roche/Chugai/Zenyaku Kogyo), 2011
Table: Sprycel (dasatinib; Bristol-Myers Squibb) – drug profile, 2011
Table: Overview of pivotal trial data for Sprycel in cancer, 2011
Table: Datamonitor's drug assessment summary of Sprycel (dasatinib; Bristol-Myers Squibb), 2011
Table: Sutent (sunitinib; Pfizer) – drug profile, 2011
Table: Overview of pivotal trial data for Sutent in cancer, 2011
Table: Datamonitor's drug assessment summary of Sutent (sunitinib; Pfizer), 2011
Table: Tarceva (erlotinib; OSI Pharmaceuticals/Genentech/Roche) – drug profile, 2011
Table: Overview of pivotal trial data for Tarceva in cancer, 2011
Table: Datamonitor's drug assessment summary of Tarceva (erlotinib; OSI Pharmaceuticals/Genentech/Roche), 2011
Table: Tasigna (nilotinib; Novartis) – drug profile, 2010
Table: Overview of pivotal trial data for Tasigna in cancer, 2011
Table: Datamonitor's drug assessment summary of Tasigna (nilotinib; Novartis), 2011
Table: Thalomid (thalidomide; Celgene) – drug profile, 2011
Table: Overview of pivotal trial data for Thalomid, 2011
Table: Datamonitor's drug assessment summary of Thalomid (thalidomide; Celgene), 2011
Table: Torisel (temsirolimus; Pfizer) – drug profile, 2010
Table: Overview of pivotal trial data for Torisel in cancer, 2011
Table: Datamonitor's drug assessment summary of Torisel (temsirolimus; Pfizer), 2011
Table: Tykerb (lapatinib; GlaxoSmithKline) – drug profile, 2011
Table: Overview of pivotal trial data for Tykerb in cancer, 2011
Table: Datamonitor's drug assessment summary of Tykerb (lapatinib; GlaxoSmithKline), 2011
Table: Vectibix (panitumumab; Amgen) – drug profile, 2010
Table: Overview of pivotal trial data for Vectibix in cancer, 2011
Table: Datamonitor's drug assessment summary of Vectibix (panitumumab; Amgen), 2011
Table: Velcade (bortezomib; Takeda/Johnson & Johnson) – drug profile, 2010
Table: Overview of pivotal trial data for Velcade in cancer, 2011
Table: Datamonitor's drug assessment summary of Velcade (bortezomib; Takeda/Johnson & Johnson), 2011
Table: Votrient (pazopanib; GlaxoSmithKline) – drug profile, 2011
Table: Overview of pivotal trial data for Votrient in cancer, 2011
Table: Datamonitor's drug assessment summary of Votrient (pazopanib; GlaxoSmithKline), 2011
Table: Xalkori (crizotinib; Pfizer) – drug profile, 2011
Table: Overview of pivotal trial data for Xalkori in cancer, 2011
Table: Datamonitor's drug assessment summary of Xalkori (crizotinib; Pfizer), 2011
Table: Yervoy (ipilimumab; Bristol-Myers Squibb) – drug profile, 2011
Table: Overview of pivotal trial data for Yervoy in cancer, 2011
Table: Datamonitor's drug assessment summary of Yervoy (ipilimumab; Bristol-Myers Squibb), 2011
Table: Zelboraf (vemurafenib; Roche/Plexxikon) – drug profile, 2010
Table: Overview of pivotal trial data for Zelboraf in cancer, 2011
Table: Datamonitor's drug assessment summary of Zelboraf (vemurafenib; Roche/Plexxikon), 2011
Table: Zolinza (vorinostat; Merck & Co.) – drug profile, 2011
Table: Overview of pivotal trial data for Zolinza (vorinostat; Merck & Co.), 2011
Table: Definition of the targeted cancer therapies market, 2011
Table: Datamonitor’s drug assessment parameters for key targeted cancer therapies

LIST OF FIGURES

Figure: Adcetris – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Adcetris (brentuximab vedotin; Seattle Genetics/Takeda) in cancer, 2011
Figure: Afinitor – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Afinitor (everolimus; Novartis) in cancer, 2011
Figure: Arzerra – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Arzerra (ofatumumab; Genmab/GlaxoSmithKline) in cancer, 2011
Figure: Avastin – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Avastin (bevacizumab; Genentech/Roche/Chugai) in cancer, 2011
Figure: Caprelsa – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Caprelsa (vandetanib; AstraZeneca) in cancer, 2011
Figure: Erbitux – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA) in cancer, 2011
Figure: Gleevec – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Gleevec (imatinib; Novartis) in cancer, 2011
Figure: Herceptin – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Herceptin (trastuzumab; Roche/Chugai) in cancer, 2011
Figure: Iressa – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Iressa (gefitinib; AstraZeneca) in cancer, 2011
Figure: Istodax – SWOT analysis in cancer, 2011
Figure: Nexavar – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Nexavar (sorafenib; Bayer Schering/Onyx) in cancer, 2011
Figure: Revlimid – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Revlimid (lenalidomide; Celgene) in cancer, 2011
Figure: Rituxan – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Rituxan (rituximab; Biogen Idec/Roche/Chugai/Zenyaku Kogyo) in cancer, 2011
Figure: Sprycel – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Sprycel (dasatinib; Bristol-Myers Squibb) in cancer, 2011
Figure: Sutent – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Sutent (sunitinib; Pfizer) in cancer, 2011
Figure: Tarceva – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Tarceva (erlotinib; OSI Pharmaceuticals/Genentech/Roche) in cancer, 2011
Figure: Tasigna – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Tasigna (nilotinib; Novartis) in cancer, 2011
Figure: Thalomid – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Thalomid (thalidomide; Celgene) in cancer, 2011
Figure: Torisel – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Torisel (temsirolimus; Pfizer) in cancer, 2011
Figure: Tykerb – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Tykerb (lapatinib; GlaxoSmithKline) in cancer, 2011
Figure: Vectibix – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Vectibix (panitumumab; Amgen) in cancer, 2011
Figure: Velcade – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Velcade (bortezomib; Takeda/Johnson & Johnson) in cancer, 2011
Figure: Votrient – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Votrient (pazopanib; GlaxoSmithKline) in cancer, 2011
Figure: Xalkori – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Xalkori (crizotinib; Pfizer) in cancer, 2011
Figure: Yervoy – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Yervoy (ipilimumab; Bristol-Myers Squibb) in cancer, 2011
Figure: Zelboraf – SWOT analysis in cancer, 2011
Figure: Datamonitor’s drug assessment summary for Zelboraf (vemurafenib; Roche/Plexxikon) in cancer, 2011
Figure: Zolinza – SWOT analysis in cancer, 2011